BIOTYPE is an innovative solution provider for molecular precision diagnostics. We are committed to advancing precision medicine through our products and services for robust analysis and interpretation of biomarker signatures. BIOTYPE offers a strong portfolio in molecular cancer diagnostics for applications in hemato-oncology, liquid biopsy, and molecular profiling of solid tumors. The portfolio includes in vitro diagnostic (IVD) tests for clinical diagnostics and research use only (RUO) assays for translational and clinical research. In addition, BIOTYPE offers high-quality and IVD compliant contract development and manufacturing services. Our proprietary MODAPLEX platform is a benchtop system for automated molecular profiling and multi-gene testing.

At BIOTYPE, we believe that the management and treatment of complex diseases can be drastically improved through better access to precision diagnostics. Our molecular testing systems are designed as integrated workflow solutions that enable our customers to get same-day results, reduced hands-on-time of their personnel, automated data analysis, and reliable performance.

BIOTYPEs processes, products, and services meet highest quality standards as we are certified according to DIN EN ISO 13485 and DIN EN ISO 9001. BIOTYPE is a part of the Molecular Diagnostics Group (MDG). The overall aim of MDG is to develop innovative products and services to improve diagnoses and therapies for precision medicine.